Adaptilens is a technology company.
Adaptilens is a technology company.
Adaptilens has raised $20.0M across 2 funding rounds.
Adaptilens has raised $20.0M in total across 2 funding rounds.
Adaptilens has raised $20.0M in total across 2 funding rounds.
Adaptilens's investors include Founder Collective, Pillar VC, Adam Gries.
Adaptilens is a medtech startup founded in 2020 that develops the Accommodating Intraocular Lens (A-IOL), a biomimetic lens designed to restore the full range of near, intermediate, and distance vision for cataract patients by mimicking the natural flexibility of a young, healthy human lens.[1][3][6] It serves primarily patients undergoing cataract surgery—expected to affect 50 million Americans by 2050—and addresses limitations of traditional monofocal IOLs, which often require glasses post-surgery and cause side effects like halos or glare.[2][6] The company has raised $20.87M total, including a $17.5M Series A led by PXV Funds just 25 days ago, fueling progression from pre-clinical to first-in-human trials.[1][2]
This funding builds on a $1.6M seed round and grants like Harvard’s President’s Innovation Challenge, signaling strong growth momentum as Adaptilens advances its patent-protected bottlebrush polymer (BBP) technology toward clinical validation.[1][4][5]
Adaptilens was founded in 2019 by Liane Clamen, MD, an ophthalmologist whose idea for a truly accommodating IOL emerged over 20 years earlier around 2002, inspired by the unmet need to replicate the youthful lens's flexibility lost in aging eyes.[4][5] Clamen, drawing from her clinical experience, partnered with experts including Duke University's Matt Becker, whose lab developed the novel BBP polymers enabling the lens to respond to ciliary muscles.[3][4]
Early traction came via accelerators like MassChallenge and Harvard Innovation Labs' Launch Lab X, where Adaptilens won $75K in the 2022 President’s Innovation Challenge for health sciences.[5] This led to seed funding from Pillar VC and Accanto Partners, followed by the pivotal Series A in 2024, marking the shift from prototype to clinical readiness.[1][5]
Adaptilens rides the aging population wave, where cataracts will double to 50 million U.S. cases by 2050 amid advances in polymer science and minimally invasive surgery.[1][6] Timing aligns with post-Harold Ridley IOL evolution—75+ years since 1949—now feasible via breakthroughs like Becker's polymers, enabling the "holy grail" of true accommodation.[3][4]
Market forces favor it: surging demand for premium IOLs (reducing glasses reliance), investor appetite for medtech (e.g., $17.5M Series A), and regulatory paths cleared by prior accommodating lens trials.[1][2] It influences ophthalmology by pushing biomimicry, potentially setting standards for vision restoration and inspiring similar nature-imitating implants in other fields.[3][5]
Adaptilens is poised for first-in-human trials in ~1.5 years, targeting market entry by 2031 with a working prototype, elite team, and fresh capital to scale manufacturing and commercialization.[1][4][5] Trends like personalized medtech, AI-optimized polymers, and value-based care for cataracts will accelerate adoption, especially as demographics strain healthcare.
Its influence could evolve from niche innovator to category leader, transforming post-cataract life for millions—validating Clamen's 20-year vision and proving biomimicry's power in restoring what nature perfected.[2][5]
Adaptilens has raised $20.0M across 2 funding rounds. Most recently, it raised $18.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $18.0M Series A | Founder Collective, Pillar VC, Adam Gries | |
| Nov 1, 2020 | $2.0M Seed | Founder Collective, Pillar VC, Adam Gries |